Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.

Back

ESC Professional Premium Access

Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.

Session: Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

Topic: Pharmacotherapy

Speaker: Professor J. Silvain (Paris, FR)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Johanne Silvain

Sorbonne University, Paris (France)

3 presentations

1 follower

4 more presentations in this session

Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis

Speaker: Miss R. Markides (Cambridge, GB)

Clopidogrel vs. aspirin in the chronic maintenance period following percutaneous coronary intervention in high thrombotic and high bleeding risk patients:sub-analysis of the HOST-EXAM Extended study

Speaker: Doctor J. Chung (Seoul, KR)

Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study

Speaker: Professor B. Lattuca (Nimes, FR)

Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention

Speaker: Doctor F. Gerardo (Amadora, PT)

Access the full session

Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

Speakers: Professor J. Silvain, Miss R. Markides, Doctor J. Chung, Professor B. Lattuca, Doctor F. Gerardo

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources